Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the first participants have been dosed in a Phase 1 clinical trial of AKB-9090, an internally developed hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor being evaluated for the treatment of cardiac surgery-associated acute kidney injury (AKI). The Phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending dose (SAD/MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AKB-9090 administered intravenously in healthy adult participants.